On Demand Webinar

Beyond Checkpoints: Strategic Use of CDX Models in Emerging IO Therapies

Cell line derived xenograft (CDX) models provide key decision-making information to allow an agent to move forward, and clients to advance their preclinical development programs in a timely and cost-effective manner.

Watch a preview:

In this expert-led webinar we explore state-of-the-art methods to enhance CDX models by integrating a complete Tumor Microenvironment (TME) and humanizing the immune system. Discover breakthrough strategies that bridge the gap between preclinical studies and clinical applications, ensuring more reliable and actionable insights for immuno-oncology (IO) therapies.

You’ll discover how to:

Enhance tumor microenvironment (TME) in CDX models to better replicate immune-tumor interactions.
Create humanized mouse models by engrafting human immune cells, allowing for IO therapy evaluation in a human immune context.
Use CDX models to refine dosing schedules for immunotherapies and combination treatments, ensuring optimal efficacy.
Utilize multiple patient-derived cell lines and genetic modifications to mimic heterogeneity and study therapy responses across different genetic backgrounds.
Perform serial biopsies and liquid biopsies in CDX models to identify mutations and biomarkers linked to resistance.

About the Presenter:

Kiel Peck, PhD, Director, Scientific Operations - San Diego, Crown Bioscience

Dr. Peck is a highly trained and experienced biologist specializing in drug discovery, development, and translational medicine. He received his PhD in Biomedical Sciences and Translational Medicine from Cedars-Sinai Medical Center in Los Angeles, California, under the guidance of the renowned cardiologist Dr. Eduardo Marban.

Prior to joining Crown Bioscience, Kiel worked extensively with small and medium-sized biotech companies to develop and advance their pre-clinical and IND-enabling drug discovery programs. Focusing mainly on product development and process optimization, he has shared multiple patents for novel manufacturing and bioengineering processes related to this work. He has successfully guided multiple drug discovery programs through the pre-IND process and onto successful IND filings. Kiel’s knowledge and experience in the early drug development pipeline provide him with the expertise and perspective to share with Crown Bioscience clients and collaborators.

Dr. Peck’s background in translational medicine positions him well to collaborate with Crown Bioscience clients as they advance their own programs through the rigors of science and regulatory approval. Kiel’s role at Crown Bioscience is to provide our clients with the knowledge and experience needed to help design and execute studies laser-focused on advancing their drug development platforms, regardless of their stage. From proof-of-concept and dose-finding studies through safety toxicology, biodistribution, and on to full efficacy studies. Kiel has experience in a wide range of critical IND-enabling studies that are foundational to the development and progression of new drug candidates.